country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-W110138

Copy Link Print Information

Chloroxoquinoline

Chloroxoquinoline is an anticancer agent. Chloroxoquinoline damages the DNA templates of cancer cells, inducing DNA breaks and cell death, and inhibits cell invasion via down-regulating Rho/Rho kinase signaling pathway. Chloroxoquinoline enhances the radiation sensitivity of Lewis lung cancer cells and xenograft tumors in tumor-bearing mouse models but decreases efficacy after long term exposure in rat models by auto-induction effects on CYP1A and CYP3A. Chloroxoquinoline has a broad-spectrum anticancer activity, such as non-small-cell lung carcinoma (NSCLC), breast cancer and gastric cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 23833-97-8
分子式: C₉H₆ClNO
分子量:179.60

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (269 KB)

Chloroxoquinoline 構造式

CAS 番号: 23833-97-8

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示 :

Cytochrome P450 アイソフォーム固有の製品をすべて表示 :

ROCK アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
BGC-823	IC₅₀	>10 μM Compound: 11	Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay	[PMID: 30496987]
BGC-823	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
BGC-823	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human BGC823 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28942112]
DLD-1	IC₅₀	>10 μM Compound: 11	Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay	[PMID: 30496987]
HCT-116	IC₅₀	>10 μM Compound: 11	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30496987]
HCT-116	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28942112]
HCT-8	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
HCT-8	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human HCT8 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28942112]
HeLa	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
HeLa	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28942112]
HEp-2	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
HEp-2	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human Hep2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28942112]
HepG2	IC₅₀	>10 μM Compound: 11	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30496987]
HepG2	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
HepG2	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28942112]
MCF7	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
MCF7	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28942112]
NCI-H1650	IC₅₀	>10 μM Compound: 11	Cytotoxicity against human NCI-H1650 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells after 48 hrs by MTT assay	[PMID: 30496987]
PC-3	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 28757067]
PC-3	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28942112]
RKO	IC₅₀	>10 μM Compound: 11	Cytotoxicity against human RKO cells after 48 hrs by MTT assay Cytotoxicity against human RKO cells after 48 hrs by MTT assay	[PMID: 30496987]
RKO	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28942112]
SK-OV-3	IC₅₀	>10 μM Compound: 11	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 30496987]

化学情報

CAS 番号 23833-97-8
分子量 179.60
分子式 C₉H₆ClNO
SMILES

O=C1C=CNC2=C1C=CC(Cl)=C2
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (269 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Li X, et al. Auto-Induction Effect of Chloroxoquinoline on the Cytochrome P450 Enzymes of Rats Associated with CYP 3A and 1A. PLoS One. 2015 Sep 23;10(9):e0138875. [Content Brief]

[2]. Liu J, et al. [Chloroxoquinoline inhibits invasion in breast cancer via down-regulating Rho/Rho kinase signaling pathway]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019 Dec 25;48(6):631-637. Chinese. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Chloroxoquinoline

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

Cytochrome P450 アイソフォーム固有の製品をすべて表示

ROCK アイソフォーム固有の製品をすべて表示

生物活性

製品説明

Cellular Effect

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Bioz

Keywords

最近チェックした製品

Chloroxoquinoline

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

Cytochrome P450 アイソフォーム固有の製品をすべて表示

ROCK アイソフォーム固有の製品をすべて表示

生物活性

製品説明

Cellular Effect

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs